Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2004;328:288-289 (31 January), doi:10.1136/bmj.328.7434.288-d
| The first 150 words of the full text of this article appear below. |
EDITORMorris et al emphasise that in acute gout lower doses of colchicine are effective yet less toxic than traditional regimens.1 Certain points need, however, to be considered.
In all the three cases quoted the patients initially started taking higher (traditional) doses of colchicine and only after they had experienced adverse effects were their doses reduced. This means a lingering effect of colchicine would be present. Evidence shows that colchicine will be present in leucocytes (site of action) for at least nine days after a single intravenous dose.2 To claim that a lower dose of colchicine is effective, should one not start with a lower dose?
Because toxicity is more common with colchicine, non-steroidal anti-inflammatory drugs (NSAIDs, such as indomethacin or naproxen) are preferred.2 In one of the three cases mentioned, meloxicam was tried without benefit. Meloxicam is a drug with a long half life, and it needs time
G Sivagnanam, additional professor of pharmacology
Chengalpattu Medical College, Chengalpattu, Tamil Nadu 603 001, India drsivagnanam@hotmail.com